What Mediately does

Mediately is a Slovenia-based medical decision-support company operating under the legal entity Modra Jagoda d.o.o., headquartered in Ljubljana and founded in 2011 by two physicians. The company operates a mobile-first and web platform that delivers localized drug information, drug interaction checking, dosage guidance, ICD-10/ATC code lookup, and a suite of clinical calculators (BMI, Body Surface Area, Creatinine Clearance) to healthcare professionals. Its core differentiator is country-specific drug databases sourced from official regulators across 14 European markets - including MSP for France, AEMPS for Spain, Rote Liste/BfArM for Germany, and SÚKL for the Czech Republic - combined with an AI assistant named Elly that performs natural-language question answering over local regulatory (RCP/SPC) documents that general-purpose AI tools cannot access. The application also provides a first-to-market drug interaction resolution module that suggests alternative medications to replace those causing problematic interactions.

The business model is a multi-stream freemium architecture. The free tier offers basic drug lookup and tool access, while the Mediately PRO subscription unlocks drug interaction checking with alternative suggestions, usage restrictions for renal/hepatic impairment, pregnancy and lactation, offline access, and priority support. A separate B2B channel targets pharmaceutical companies through a dedicated portal (pharma.mediately.co) offering advertising placements, enterprise-tier PRO subscriptions, and data licensing of the curated drug corpus. Distribution is primarily product-led through the iOS App Store and Google Play Store with localized country web properties; no enterprise sales-led motion is evident. Marketing relies on localized SEO, app-store optimization, and word-of-mouth referral among the installed base.

Mediately claims 700,000+ healthcare professional users across 14 countries, comprising approximately 300,000 physicians, 63,000 pharmacists, and 360,000 other HCPs, supported by a 4.9 average app-store rating across 36,000+ ratings. The company has raised approximately €7.6 million in disclosed funding across multiple early rounds and a €7.2 million Series A in February 2022 led by Piton Capital, with LAUNCHub Ventures, Silicon Gardens, and VentureFriends participating. Stated strategic intent is to expand penetration from 300,000 doctors toward the 1.7 million doctors across Europe as the total addressable target.

Name

Mediately

Legal name

Modra Jagoda, spletno oblikovanje in razvoj mobilnih aplikacij d.o.o.

Website

https://mediately.co

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Mediately provides a mobile and web medical decision-support platform serving 700,000+ European healthcare professionals with localized drug databases, drug interaction checking, AI assistant Elly, and clinical tools across 14 countries, monetized via PRO subscriptions, pharma advertising, and data licensing.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

akta.pro primary industry

Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG)

Keywords

• Drug information platform
• Clinical decision support
• Medical reference app
• Drug interaction checker
• Pharmaceutical database software

Headquarters

HQ city

Ljubljana

HQ country

Slovenia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. PRO Subscription: Freemium model with premium PRO subscription offering drug interaction checking, offline access, usage restrictions, and priority support. Monthly and annual billing options with 7-day free trial.
2. Advertising to Pharmaceutical Companies: Advertising platform targeting healthcare professionals (https://pharma.mediately.co)
3. Data Licensing: Licensing of drug data and medical content to third parties.
4. PRO for Companies: B2B enterprise offerings for pharmaceutical companies providing specialized business PRO packages.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Mediately operates a mobile and web application that delivers instant, locally-sourced drug information, drug interaction checking with alternative medication suggestions, ICD-10/ATC medical coding lookup, clinical calculators, and AI-powered Q&A (Elly) to healthcare professionals across 14 European countries. A freemium model provides basic drug lookup free of charge, while the Mediately PRO subscription unlocks interaction resolution, usage restriction previews, offline access, and priority support. A separate PRO for Companies offering targets pharmaceutical companies with advertising and data licensing opportunities.

Product overview

Mediately is a medical decision support platform consisting of a core mobile/web application offering drug information, interaction checking, and medical coding tools, supplemented by a premium Mediately PRO subscription tier. The platform integrates AI capabilities through its AI Mode feature and AI assistant Elly for natural language-based drug information retrieval. Additional offerings include specialized medical calculators (Creatinine Clearance, BMI), classification lookup tools (ATC, ICD-10), and a standalone drug interactions checker. The company also offers a business-pro version targeting pharmaceutical companies. The platform is localized for 14 countries, serving over 700,000 healthcare professionals including 300,000 doctors, 63,000 pharmacists, and 360,000 other healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

• Mediately PRO: Premium subscription version offering additional features including drug interaction checking, offline drug information access, usage restriction viewing, and priority support.

Products and services

• Mediately App Mobile and web application providing instant access to local drug information databases, ICD codes, ATC codes, drug interaction checking, and clinical tools for healthcare professionals across 14 European countries. Free tier covers basic drug information and tools.
• Mediately PRO

Quantifiable outcome

• Over 700,000 healthcare professionals use the platform
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Epocrates: Mobile drug reference and clinical decision support app for physicians, offering drug interaction checking, dosing, and formulary information. Most direct functional analog to Mediately, though primarily US-focused and now owned by Wolters Kluwer.
• Drugs.com: Consumer and professional drug information platform providing monographs, interaction checking, and pill identification. Comparable in drug reference function and pharma-supported business model, though less localized for European regulatory sources.

Broad incumbents

• UpToDate: Comprehensive clinical decision support resource covering drug information, disease topics, and treatment guidelines. Wolters Kluwer-owned, used by HCPs globally. Comparable in serving HCP drug information needs but operates as a broad evidence-based reference rather than a mobile-first localized tool.
• Medscape: WebMD's flagship HCP platform offering drug reference, medical news, CME, and clinical tools. Comparable target audience (physicians) and freemium model with pharma advertising, though broader scope than Mediately and primarily US-anchored.
• Lexicomp: Drug information and clinical decision support solution from Wolters Kluwer, widely used in hospital and pharmacy settings. Direct overlap with Mediately's drug interaction and dosing tools, but typically sold as an enterprise license rather than mobile freemium.
• First Databank (FDB): Drug knowledge and medication decision support provider whose data powers many EHR-embedded drug reference tools. Comparable in providing the underlying drug data layer; competes with Mediately at the data licensing stream.
• Dedalus: European healthcare IT vendor providing EHR and clinical software to hospitals across Italy, Germany, France, and other markets Mediately serves. Threat vector as it embeds drug reference functionality into clinical workflows.

Regional players

• VIDAL Group: Leading French drug information database used by HCPs and integrated into hospital systems. Directly comparable to Mediately's drug reference function, particularly in the French market, though more institutionally embedded than mobile-first.
• DocMorris: European online pharmacy operating across multiple Mediately-served countries (Germany, Netherlands, Switzerland, etc.). Overlaps in pharma and HCP-facing services, though focused on dispensing rather than clinical reference.

Emerging players

• Sermo: HCP social network and drug reference platform monetized via pharma market research and advertising. Comparable in serving verified HCPs with pharma-funded business model, though more weighted to physician community than drug reference.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mediately
• Facebookfacebook.com/Mediately

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mediately